Please assess the completion status of the following clinical trial:

Trial Title: Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria~* Healthy male subjects, healthy female subjects of non-childbearing potential, 18-55 years of age (Part 1)~* Male subjects, female subjects of non-childbearing potential, female subjects of childbearing potential with documented bilateral tubal ligation (tubes tied) or bilateral salpingectomy (tubes removed), 18-65 years of age, and 2 of the following symptoms: nasal congestion/obstruction, nasal discharge, face pain/pressure,or reduction/loss of smell (Part 2)~* Male or female subjects between the ages of 18 and 75 years, inclusive with moderate-to-severe Atopic Dermatitis, agree to avoid prolonged exposure to the sun and not to use tanning booths, sun lamps, or other ultraviolet light sources during the study (Part 3)~Exclusion Criteria:~* Clinically significant diseases (cardiac, psychiatric, autoimmune, renal, etc.), positive urine drug test, fever within 7 days of dosing, active infections within 28 days of dosing (Part 1 and 2 and 3)~* History of allergic reaction to topical lidocaine, nasal surgery within 6 months (Part 2)~* Exposure to live or attenuated vaccines, have skin conditions other than Atopic Dermatitis, use of JAK inhibitors and biologics (Part 3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 10 mg of PF-06817024 or placebo
- Cohort 2 (Type: EXPERIMENTAL): 30 mg of PF-06817024 or placebo
- Cohort 3 (Type: EXPERIMENTAL): 100 mg of PF-06817024 or placebo
- Cohort 4 (Type: EXPERIMENTAL): 300 mg of PF-06817024 or placebo
- Cohort 5 (Type: EXPERIMENTAL): 1000 mg of PF-06817024 or placebo
- Cohort 6 (Type: EXPERIMENTAL): 2000 mg of PF-06817024 or placebo
- Cohort 7 (Type: EXPERIMENTAL): 30 mg subcutaneous dose of PF-06817024 or placebo
- Cohort 8 (Type: EXPERIMENTAL): 300 mg of PF-06817024 or placebo
- Cohort 9 (Type: EXPERIMENTAL): IV dose to be determined of PF-06817024 or placebo
- Cohort 10 (Type: EXPERIMENTAL): PF-06817024 or placebo
- Cohort 11 (Type: EXPERIMENTAL): PF-06817024 or placebo
- Cohort 12 (Type: EXPERIMENTAL): PF-06817024 or placebo
- Cohort 13 (Type: EXPERIMENTAL): PF-06817024 or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).